Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized trial to assess the efficacy of interferon-alpha daily in combination with ribavirin in the treatment of naïve patients with chronic hepatitis C.
Tassopoulos NC, Ketikoglou I, Tsantoulas D, Raptopoulou M, Hatzis G, Vafiadis I, Sidiropoulos L, Kanatakis S, Anagnostopoulos G, Sypsa V, Hatzakis A; Hellenic Viral Hepatitis Research Network. Tassopoulos NC, et al. Among authors: hatzis g. J Viral Hepat. 2003 Sep;10(5):383-9. doi: 10.1046/j.1365-2893.2003.00439.x. J Viral Hepat. 2003. PMID: 12969190 Clinical Trial.
Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection.
Sypsa V, Touloumi G, Tassopoulos NC, Ketikoglou I, Vafiadis I, Hatzis G, Tsantoulas D, Akriviadis E, Delladetsima J, Demonakou M, Hatzakis A. Sypsa V, et al. Among authors: hatzis g. J Viral Hepat. 2004 Jul;11(4):366-74. doi: 10.1111/j.1365-2893.2004.00517.x. J Viral Hepat. 2004. PMID: 15230860
The effect of adherence to therapy on sustained response in daily or three times a week interferon alpha-2b plus ribavirin treatment of naive and nonresponder chronic hepatitis C patients.
Raptopoulou M, Tsantoulas D, Vafiadi I, Ketikoglou I, Paraskevas E, Vassiliadis T, Kanatakis S, Hatzis G, Sidiropoulos L, Akriviadis E. Raptopoulou M, et al. Among authors: hatzis g. J Viral Hepat. 2005 Jan;12(1):91-5. doi: 10.1111/j.1365-2893.2005.00549.x. J Viral Hepat. 2005. PMID: 15655054
Molecular epidemiology of hepatitis C virus (HCV) in Greece: temporal trends in HCV genotype-specific incidence and molecular characterization of genotype 4 isolates.
Katsoulidou A, Sypsa V, Tassopoulos NC, Boletis J, Karafoulidou A, Ketikoglou I, Tsantoulas D, Vafiadi I, Hatzis G, Skoutelis A, Akriviadis E, Vasiliadis T, Kitis G, Magiorkinis G, Hatzakis A. Katsoulidou A, et al. Among authors: hatzis g. J Viral Hepat. 2006 Jan;13(1):19-27. doi: 10.1111/j.1365-2893.2005.00649.x. J Viral Hepat. 2006. PMID: 16364078
Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort.
Papatheodoridis GV, Manolakopoulos S, Touloumi G, Nikolopoulou G, Raptopoulou-Gigi M, Gogos C, Vafiadis-Zouboulis I, Karamanolis D, Chouta A, Ilias A, Drakoulis C, Mimidis K, Ketikoglou I, Manesis E, Mela M, Hatzis G, Dalekos GN; HepNet.Greece Study Group. Papatheodoridis GV, et al. Among authors: hatzis g. J Viral Hepat. 2015 Feb;22(2):120-7. doi: 10.1111/jvh.12283. Epub 2014 Jul 15. J Viral Hepat. 2015. PMID: 25040685
Association of antiviral therapy with reduced disease progression in chronic Hepatitis B patients: Results from a nation-wide cohort study.
Vourli G, Papatheodoridis G, Raptopoulou M, Dalekos GN, Hounta A, Nikolopoulou G, Zouboulis-Vafeiadis I, Manesis E, Kitis G, Gogos C, Ketikoglou I, Hatzis G, Vasilialdis T, Karatapanis S, Mimidis K, Drakoulis C, Touloumi G, The Hepnet-Greece. Vourli G, et al. Among authors: hatzis g. Hippokratia. 2016 Jul-Sep;20(3):214-221. Hippokratia. 2016. PMID: 29097888 Free PMC article.
76 results